Adalimumab biosimilar - Coherus BioSciences

Drug Profile

Adalimumab biosimilar - Coherus BioSciences

Alternative Names: CHS-1420

Latest Information Update: 08 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Coherus Biosciences
  • Developer Coherus BioSciences
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Plaque psoriasis

Most Recent Events

  • 07 Sep 2017 The Patent Trial and Appeal Board of the USPTO denies institution of all four of its petitions for Inter Partes Review of AbbVie’s US patent 9 085 619 related to adalimumab
  • 28 Aug 2017 Pharmacokinetics and adverse events data from a phase I trial in healthy volunteers released by Coherus BioSciences
  • 07 Aug 2017 Coherus BioSciences anticipates a BLA submission in USA in the first half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top